ECT2 and adenocarcinoma in situ: Early studies on genetics and epigenetics of LUAD reveal that epithelial cell transforming sequence 2 (ECT2) is differentially expressed in both adenocarcinoma in situ (AIS) and early invasive adenocarcinoma [4], suggesting that ECT2 may be a new entry point for LUAD treatment.